A practical reference on immunomodulatory peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-21. Anything still debated is marked as such rather than presented as settled.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Acetylated peptide | N-terminal acetyl group blocks aminopeptidase attack |
| Residue count | 28 amino acids | Matches the N-terminus of prothymosin alpha |
| Molecular mass | About 3,108 Da | Value for the free, unmodified peptide |
| Isoelectric point | Approximately 4.2 | Acidic; net negative charge at neutral pH |
| Encoding gene | PTMA | Human gene for the precursor protein |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
Lyophilized thymosin alpha 1 is typically stored refrigerated at 2 to 8 degrees Celsius and kept away from light. Reconstituted solutions are less stable and are usually used promptly after preparation. Repeated freeze-thaw cycles are avoided because they can promote aggregation and loss of activity. The peptide adsorbs to some plastic and glass surfaces, so a carrier protein is often added to dilute working solutions. Manufacturer instructions and published protocols both govern handling.
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
Their first son Prince Aegon was born in 120 AC, while their second son was born in 122 AC and named after Viserys. In 126 AC, Rhaenyra requested that Luke be recognized as the heir to Driftmark, which several members of House Velaryon protested under the accusation that he was not Laenor's son. As Viserys angrily ordered their tongues to be cut out, he slipped and cut his hand on the Iron Throne, a severe injury that gave him a fever from infection. Some maesters feared that he would die, but Viserys lived after two of his fingers were removed by Maester Gerardys, and he would never sit on the Iron Throne again. Gerardys was recommended by Rhaenyra as a replacement for the dead Grand Maester Mellos, while Alicent recommended Maester Alfador, her family's maester. Viserys decided to appoint neither man as Grand Maester and deferred to the Citadel to fill the office, who chose Maester Orwyle. As Viserys' health gradually weakened, Otto filled the small council with members loyal to the greens, including Lord Larys Strong, Ser Tyland Lannister, and Ser Jasper Wylde. Lord Commander of the Kingsguard Criston Cole was also an ardent supporter of Alicent, with Orwyle being politically neutral and Lord Lyman Beesbury opposing the greens. Viserys passed away in his sleep in 129 AC, having been discovered by a servant who informed Alicent of his status. In the interim, Alicent did not disclose Viserys' death to the public and summoned the small council to a secret meeting.
890A Ammunition Warrant Officer 913A Armament Systems Maintenance Warrant Officer 914A Allied Trades Warrant Officer 915A Automotive Maintenance Warrant Officer 915E Senior Automotive Maintenance Warrant Officer 919A Engineer Equipment Maintenance Warrant Officer 948B Electronic Systems Maintenance Warrant Officer 948D Electronic Missile Systems Maintenance Warrant Officer 948E Senior Electronics Maintenance Warrant Officer Enlisted
Phenadoxone (trade names Heptalgin, Morphidone, and Heptazone) is an opioid analgesic of the open chain class (methadone and relatives) invented in Germany by Hoechst in 1947. It is one of a handful of useful synthetic analgesics which were used in the United States for various lengths of time in the 20 or so years after the end of the Second World War but which were withdrawn from the market for various or no known reason and which now are mostly in Schedule I of the United States' Controlled Substances Act of 1970, or (like phenazocine and bezitramide) in Schedule II but not produced or marketed in the US. Others on this list are ketobemidone (Ketogin), dextromoramide (Dimorlin, Palfium and others), phenazocine (Narphen and Prinadol), dipipanone (Diconal, Pipadone and Wellconal), piminodine (Alvodine), propiram (Algeril), anileridine (Leritine) and alphaprodine (Nisentil). Phenadoxone has a US DEA ACSCN of 9637 and has had a zero annual manufacturing quota under the Controlled Substances Act 1970. Its withdrawal from US distribution prior to the promulgation of said act is a large part of its Schedule I designation; it is, however, used as a legitimate medication in other countries and consumption is increasing worldwide as indicated below. Phenadoxone is generally considered to be a strong opioid analgesic and is regulated in much the same way as morphine where it is used. The usual starting dose is 10–20 mg and it has a duration of analgesic effect of 1 to 4 hours. Phenadoxone is not used at this time for purposes other than pain relief.
Ewan Gordon McGregor ( YOO-ən; born 31 March 1971) is a Scottish actor and filmmaker. His accolades include a Golden Globe Award and a Primetime Emmy Award. In 2013, he was appointed Officer of the Order of the British Empire (OBE) for his service to drama and charity. While studying drama at the Guildhall School of Music and Drama, McGregor began his career with a leading role in the British series Lipstick on Your Collar (1993). He gained international recognition for starring as drug addict Mark Renton in Trainspotting (1996), and as Obi-Wan Kenobi in the Star Wars prequel trilogy (1999–2005). His career progressed with starring roles in the musical Moulin Rouge! (2001) for which he was nominated for the AACTA Award for Best Actor in a Leading Role, action film Black Hawk Down (2001), fantasy film Big Fish (2003), and thriller Angels and Demons (2009). He was praised for his performances in the thriller The Ghost Writer (2010) and the romantic comedy Salmon Fishing in the Yemen (2011). McGregor made his directorial debut with the crime film American Pastoral (2016), in which he also starred. For his dual role as brothers Ray and Emmit Stussy in the third season of the anthology series Fargo (2017), he won the Golden Globe Award for Best Actor – Miniseries or Television Film. He portrayed and voiced Lumière in Beauty and the Beast (2017), and played the title role in Christopher Robin (2018), Dan Torrance in Doctor Sleep (2019), and Black Mask in Birds of Prey (2020).
Sources: en.wikipedia.org
Thickening foliage provided the insurgents with concealment from South African patrols, and their tracks were obliterated by the rain. At the end of April or early May, PLAN cadres returned to Angola to escape renewed SADF search and destroy efforts and retrain for the following year. Another significant factor of the physical environment was South West Africa's limited road network. The main arteries for SADF bases on the border were two highways leading west to Ruacana and north to Oshikango, and a third which stretched from Grootfontein through Kavangoland to Rundu. Much of this vital road infrastructure was vulnerable to guerrilla sabotage: innumerable road culverts and bridges were blown up and rebuilt multiple times over the course of the war. After their destruction PLAN saboteurs sowed the surrounding area with land mines to catch the South African engineers sent to repair them. One of the most routine tasks for local sector troops was a morning patrol along their assigned stretch of highway to check for mines or overnight sabotage. Despite their efforts, it was nearly impossible to guard or patrol the almost limitless number of vulnerable points on the road network, and losses from mines mounted steadily; for instance, in 1977 the SADF suffered 16 deaths due to mined roads. Aside from road sabotage, the SADF was also forced to contend with regular ambushes of both military and civilian traffic throughout Ovamboland.
multiple cloning site (MCS) Also polylinker. A locus or sequence within a plasmid vector which contains multiple unique restriction sites recognized by various restriction endonucleases, which makes it possible for scientists to target the insertion of a DNA fragment (often a gene cassette) specifically to that locus and in the desired orientation, by digesting the insert and the vector with the same endonuclease(s) and then ligating them together via compatible restriction ends, a technique known as restriction cloning. Commercial plasmids designed for cloning commonly incorporate one or more multiple cloning sites.
=== Cardiovascular diseases === In the 1930s, polyphenols (then called vitamin P) were considered as a factor in capillary permeability, followed by various studies through the 21st century of a possible effect on cardiovascular diseases. For most polyphenols, there is no evidence for an effect on cardiovascular regulation, although there are some reviews showing a minor effect of consuming polyphenols, such as chlorogenic acid or flavan-3-ols, on blood pressure.
Crystallization of ubiquitin protein was successfully done using racemic crystallography. Crystallization of either D-ubiquitin or L-ubiquitin alone is difficult, whereas a racemic mixture of D-ubiquitin and L-ubiquitin was readily crystallized and diffraction quality crystals were obtained overnight in almost half the conditions tested in a standard commercial crystallization screen. Crystallization of racemates of disulfide-containing microprotein molecules was used to determine the structure of trypsin inhibitor SFTI-1 (14 amino acids,1 disulfide), conotoxin cVc1.1 (22 amino acids, 2 disul-fides) and cyclotide kB1 (29 amino acids, 3 disulfides). Using X-ray diffraction, it was found that the racemates crystallized in the centrosymmetric spacegroups P3(bar), Pbca and P1(bar). Interestingly, achiral "'peptoid'" chains were found to fold as racemic pairs and crystallize in highly preferred centrosymmetric space groups. A high-resolution crystal structure of the racemate of a heterochiral D-protein complex with vascular endothelial growth factor A (VEGF-A). The mirror image D-protein form of VEGF-A was used in phage display to identify a 56 residue L-protein binder with nanomolar affinity; the chemically synthesized D-protein binder had the same affinity for the L-protein form of VEGF-A. A mixture of chemically synthesized proteins consisting of D-VEGF-A, L-VEGF-A, and two equivalents each of the D-protein binder and L-protein binder, gave racemic crystals in the centrosymmetric space group P21/n.
At the start of 2014, the company out-licensed its Friedreich's ataxia program, including a library of histone deacetylase inhibitor compounds, to BioMarin Pharmaceutical for US$2,000,000 and future milestone and royalty payments. Repligen has made several acquisitions through the early 2020s, including BioFlex Solutions and Tantti Laboratory Inc. among others. As of 2024, the company's President and Chief Executive Officer is Olivier Loeillot. As of 2025 it employs approximately 2,000 employees across several sites in the United States, Europe, and Asia.
Sources: en.wikipedia.org
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.